BiotechTube

APL-2 + APL-2

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy

Trial Timeline

Aug 31, 2018 → Jun 20, 2022

NCT ID
NCT03525600

About APL-2 + APL-2

APL-2 + APL-2 is a phase 3 stage product being developed by Apellis Pharmaceuticals for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03525600. Target conditions include Geographic Atrophy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT03525600Phase 3Completed
NCT03525613Phase 3Completed

Competing Products

20 competing products in Geographic Atrophy

See all competitors
ProductCompanyStageHype Score
avacincaptad pegolAstellas PharmaPhase 3
77
Avacincaptad PegolAstellas PharmaPhase 2/3
65
avacincaptad pegolAstellas PharmaApproved
85
Avacincaptad pegol (ACP)Astellas PharmaPre-clinical
23
Avacincaptad Pegol + ShamAstellas PharmaPhase 3
77
ABBV-6628 + SYFOVREAbbViePhase 1/2
41
FWY003 + PlaceboNovartisPhase 2
52
CLG561 + LFG316 + Sham injectionNovartisPhase 2
52
LFG316 + Sham + LFG316 Lower doseNovartisPhase 2
52
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
RO7669330 + Syfovre™ + Izervay™RochePhase 1
33
RO7303359RochePhase 1
33
SAR446597 + Sham ComparatorSanofiPhase 1/2
40
PozelimabRegeneron PharmaceuticalsPhase 1
32
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)Ionis PharmaceuticalsPhase 2
49
Tinlarebant + PlaceboBelite BioPhase 3
74
PegcetacoplanApellis PharmaceuticalsPre-clinical
18
APL-2, PegcetacoplanApellis PharmaceuticalsPhase 3
72

Other Products from Apellis Pharmaceuticals

PegcetacoplanPhase 3
72
APL-2, PegcetacoplanPhase 3
72
APL-2Phase 3
72
PegcetacoplanPhase 3
72
PegcetacoplanPhase 3
72